StephanieLynn(Schutt)GraffMD

Breast Cancer, Hematologic Oncology

Physician

Dr. Graff is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
2316 E Meyer Blvd
1 Cancer West
Kansas City, MO 64132
Phone+1 816-276-4700

Fax+1 816-276-3810

University of Kansas School of MedicineFellowship, Hematology and Medical Oncology, 2008 - 2011
University of Missouri-Kansas City School of MedicineResidency, Internal Medicine, 2004 - 2007
University of Missouri Kansas City School of MedicineClass of 2004

PubMed

2 citations
Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial.
Kevin Kalinsky, Giampaolo Bianchini, Erika Hamilton, Stephanie L Graff, Kyong Hwa Park
Journal of Clinical Oncology. 2025-03-20
Signaling pathway dysregulation in breast cancer.
Dinara Ryspayeva, Attila A Seyhan, William J MacDonald, Connor Purcell, Tyler J Roady
Oncotarget. 2025-03-13
Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine: Bringing next-generation precision oncology to patients.
Wafik S El-Deiry, Catherine Bresson, Fanny Wunder, Benedito A Carneiro, Don S Dizon
Oncotarget. 2025-03-12

Abstracts/Posters

WhatÍs in a Name? a Gender-Based Analysis of Speaker Introductions at the American Society of Hematology Annual Meeting
Stephanie L. Graff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

How Close Is Too Close: Navigating Difficult Situations
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

‘Clinically Meaningful’ Outcomes in Cancer Care Extend Beyond SurvivalFebruary 3rd, 2025
The Oncology Brothers Advancements in Oncology: What Community Oncologists Can Bring to Their Practice of Breast CancerJanuary 7th, 2025
Muddier Waters and an FDA Approval? Phase 3 Imlunestrant Data May Shake Up Breast Cancer CareJanuary 3rd, 2025
Join now to see all